- The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders
- The initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needs
- PFN’s development for its proprietary drug candidate, TRP-8803, focuses on increased efficacy, natural blood-brain barrier penetration, enhanced safety and toxicity profiles, reduced risk of abuse, and reduced risk of addiction
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a San Diego-based pharmaceuticals company, has joined the lineup of presenters at this year’s Canaccord Genuity Virtual Growth Conference, to be held virtually on August 10-12. Tryp is focused on developing psilocybin-based clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways (https://ibn.fm/gxu6h).
Tryp Chairman and CEO Greg McKee stated that the company would be presenting an overview of the business and its pipeline – including Tryp’s Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders. Tryp’s presentation will be held on August 10 at 3 p.m. EST. Register to view the presentation at https://ibn.fm/ja8ep.
Prior to this announcement, Tryp released a broadcast titled, “Psychedelics – Not Just for Mental Health Anymore,” highlighting the historical knowledge of psychedelics, such as peyote and psilocybin, and their healing effects, (https://ibn.fm/6c1sq). Modern-day research was hindered by the Controlled Substances Act of 1970, classifying psychedelics as Schedule I drugs with no medical use.
In the last few years, research has been lifting this stigma, including research done by Johns Hopkins Medical showing that two doses of psilocybin in combination with psychotherapy generated reduced symptoms for adults suffering from major depression. (can we link to the trial here). Many psychedelic companies have focused on depression, but Tryp is confident that psilocybin can effectively treat other underserviced indications, including chronic pain and certain eating disorders.
Tryp’s PFN program is focused on the development of psilocybin-based drug therapy for certain neuropsychiatric disorders. The psilocybin-based therapies have distinct advantages over other drugs currently on the market or in development, including:
- Increased efficacy
- Natural blood-brain barrier penetration
- Enhanced safety and toxicity profiles
- Reduced risk of abuse
- Reduced risk of addiction
PFN features Tryp’s lead drug candidate, TRP-8802, with an initial indication of fibromyalgia. Tryp plans to seek FDA approval to proceed to Phase 2a clinical trials to evaluate the drug as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients found in TRP-8802.
So far in 2021, Tryp has achieved significant milestones, which include expanding its roster of world-class scientific advisors, initiating collaborations with world-renowned research institutions to advance clinical trials, advancing the manufacturing capability for synthetic psilocybin, and more. Tryp plans to continue achieving several other milestones before the end of 2021. These milestones include initiating at least two Phase 2a trials, announcing several new clinical research collaborations with leading academic research institutions, successful manufacturing and formulation of GMP synthetic psilocybin using proprietary methods, and filing for additional intellectual property applications.
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
